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Introduction. Pituitary adenomas represent 10–20% of all intracranial tumors and are mostly hormone-secreting (about 75%).
Endoscopic Endonasal Transsphenoidal Resection (EETR) is themainstay treatment of symptomatic cases or refractory tomedical
therapy and FSRT is often an integral part of postoperative treatment.
Purpose. The aim of this study is to evaluate the efﬁcacy and safety of SFRT in pituitary adenomas.
Methods and materials. Between December 2009 and February 2013, 10 patients with pituitary adenoma (6 males and 4 females)
treated with SFRT were assessed prospectively. Nine patients underwent primary surgery (8 transsphenoidal resection and 1
subfrontal craniotomy) and 1 was unresectable. Median gross tumor volume (GTV) was 3.4 cc (range 0.8–24.6). A median dose of
50Gy (range 48–50Gy) was prescribed to the 98% of PTV (GTV plus 2.5mm margin). Median maximal dose to organs at risk was
as follows: 48.75Gy to chiasm (range 34.5–50.9) and 48.5Gy to brainstem (range 15–53).
Results. Median age was 50.5 years (range 30–83). Six tumors (60%) were secretory (3 growth hormone, 2 adrenocorticotropic
hormone and 1 prolactin) and 4(40%) non secretory. SFRT was indicated for residual, recurrent and unresectable tumor in 8.1,
and 1 patient respectively. With a median time follow up of 11 months (range 8–25) tumor control rate was 100% (7 reduction
disease and 3 stable disease). Hormonal control was achieved in 2/10 patients. Postoperative panhypopituitarism (5) and visual
deﬁcit (4) remained the same after FSRT. None of 10 patients developed radiation induced toxicity according to CTCAE scale.
Conclusions. FSRT is a safe and effective treatment in residual or recurrent adenoma pituitary after resection surgery but long
term follow up is required to determine control in secretory tumors.
http://dx.doi.org/10.1016/j.rpor.2013.03.538
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Introduction. The role of whole brain irradiation (WBI) in the treatment of metastatic brain disease is controversial since data
available support, at least, no inferiority in overall survival and a better toxicity proﬁle in more selective and accurate irradiation
techniques. Moreover, the salvage irradiation after WBI failure remains challenging.
Purpose. The aim of our study was to assess the initial results provided by fractionated stereotactic radiotherapy (FSRT) for brain
metastasis treated in our institution.
Materials and methods. Between June 2010 and October 2012, 76 lesions from 43 patients with a single or multiple (up to 5)
intracranial metastasis were treated with FSRT as a primary treatment (24p), after surgical resection (7p) or after WBI failure
(13p). Fractionation schedules were 7×5Gy (n=28) and 5×5Gy (n=15) when WBI or surgery has been performed prior to FSRT.
Planning target volume enclosed the tumour or tumour resection cavity with a safety margin of 2–3 mm. Treatment was delivered
by NovalisTM 6D or Hi-Art TomotherapyTM linacs. Daily ExacTracTM or megavoltage computerized tomography images were
obtained.
Results. Median overall survival was 6.7 months, and 12-months survival was 19%. Median disease free survival was 5.18 months.
Mean cause speciﬁc survival (CNS failure related) was 22.13 months. No correlation among RPA class and outcome was observed.
Neither lesions’ size nor primary tumour histology was predictor of survival. No patient demonstrated toxicity grade 2 or higher.
Conclusion. FSRT as a primary, postoperative or salvage treatment is a feasible and well tolerated approach for the management
of single or multiple brain metastasis that could provide an effective treatment decreasing late toxicity related with WBI. Further
research is needed to establish a comparison with WBI toxicity results in long term survivors.
http://dx.doi.org/10.1016/j.rpor.2013.03.539
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Introduction. Stereotactic radiosurgery (SRS) has become increasingly used for treatment of brain metastases. A non-invasive
mask system plus Image Guided Radiotherapy (IGRT) is a very attractive and comfortable alternative.
Objective. To assess the clinical outcomes of frameless SRS for brain metastases using IGRT.
